And yet MORE good news on GLP-1s
We almost need a separate GLP-1 newsletter. Added to other great news this week (see below), the FDA just cleared Ozempic for treatment of chronic kidney disease in diabetics.
Four days ago, Novo Nordisk (the manufacturer of Ozempic) got good news on their next generation weight loss drug, amycretin. Amycretin mimics the gut hormone GLP-1, but it also mimics the effect of a hunger-suppressing pancreatic hormone called amylin.
And just a week ago, a huge Veterans Administration study was published with unexpected findings from GLP-1 administration, such as a decrease in substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimer’s disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions. Researchers have been saying for years that obesity is behind more disease processes than just obesity; this study certainly opens that door wider.
Today, the FDA approved Ozempic to treat chronic kidney disease in diabetics.
(Seey prior posts for more on GL